Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population, BMC Cancer, January 2010, Springer Science + Business Media,
DOI: 10.1186/1471-2407-10-26.
You can read the full text:
Contributors
The following have contributed to this page